Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 10, 2017. The report details a corporate action regarding a blocklisting application submitted to the Financial Conduct Authority and the London Stock Exchange Plc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of share issuance rather than a financial results report.
Material Changes
The material change disclosed is the reservation of 600,000 Ordinary shares of 25p each under block listings. These shares are designated for issuance pursuant to the GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that upon issuance, the new shares will rank pari passu with existing ordinary shares.
Investor Verification Checklist
- Confirm the admission of 600,000 Ordinary shares to the Official List.
- Verify the link between the share issuance and the 2009 Deferred Annual Bonus Plan.
- Check subsequent filings for the actual issuance date and impact on share capital.